Comparative Pharmacology
Head-to-head clinical analysis: AKRINOL versus RETIN A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKRINOL versus RETIN A.
AKRINOL vs RETIN-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
Retin-A (tretinoin) binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene expression involved in cell differentiation, proliferation, and inflammation. It increases epidermal turnover, reduces comedone formation, and stimulates collagen synthesis.
Adults: 100 mg orally twice daily.
Apply a thin layer to affected areas once daily at bedtime. Initial concentration typically 0.025% cream or 0.01% gel; titrate based on tolerability.
None Documented
None Documented
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless CrCl <30 mL/min).
Terminal elimination half-life is approximately 0.5-2 hours for the parent drug. Clinical context: Due to rapid clearance, systemic accumulation is negligible with topical use; effects persist due to retinoid-induced gene expression changes.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
After topical application, systemic absorption is minimal. The absorbed fraction is metabolized in the liver via cytochrome P450 enzymes and excreted in bile and urine as glucuronide conjugates. Renal excretion accounts for <1% of the applied dose; fecal excretion of metabolites is the primary route (<5% of applied dose).
Category C
Category C
Topical Retinoid
Topical Retinoid